FDA approves Bracco’s LumenHance
Contrast agent developer Bracco Diagnostics of Princeton, NJ, in December received Food and Drug Administration approval for its LumenHance (manganese chloride tetrahydrate) oral contrast agent for enhancing gastrointestinal MRI studies. Bracco has
Contrast agent developer Bracco Diagnostics of Princeton, NJ, in December received Food and Drug Administration approval for its LumenHance (manganese chloride tetrahydrate) oral contrast agent for enhancing gastrointestinal MRI studies. Bracco has licensed the agent from its developer, ImaRx Pharmaceutical of Tucson.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Recent Videos
Related Content
